Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today
announces it has been named the Preferred Sports Medicine Technology Partner of
UFC - the world's premier mixed martial arts organization and one of the
foremost global brands in all of sports. Under the terms of the multi-year
partnership, Smith+Nephew will activate its brand through UFC's immense global
presence to promote the repair, regeneration and recovery of Sports Medicine
injuries through advanced technologies.
"We're thrilled to have Smith+Nephew join us for the first time as an Official
UFC Partner," said Robby Miller, Vice President, UFC Global Partnerships.
"Through hard work, significant investment, and groundbreaking innovations like
the UFC Performance Institute, UFC has become the industry leader in athlete
health and safety in combat sports. We're looking forward to advancing that
mission by also promoting better health and recovery through technology
solutions, such as those offered by Smith+Nephew, that will benefit UFC athletes
and fans alike."
Smith+Nephew offers world-class Sports Medicine solutions including advanced
technologies, instruments and implants that enable surgeons to perform minimally
invasive surgery including the repair of soft tissue injuries and degenerative
conditions of the shoulder, knee, hip and small joints. Recent advancements in
its biological healing portfolio include the REGENETEN(?) Bioinductive Implant
and the newly acquired CARTIHEAL(?) AGILI-C(?) Cartilage Repair Implant. Backed
by impressive clinical evidence, both technologies are transforming the way
healthcare professionals treat soft tissue repair and helping improve patient
outcomes versus the current standard of care.(1,2)
"Smith+Nephew's purpose is Life Unlimited - helping restore people's bodies and
their self-belief by using technology to take the limits off living. We are
proud to partner with UFC and share a common goal to get patients back in the
game quickly, safely, and effectively," said Scott Schaffner, President Sports
Medicine, Smith+Nephew. "The global reach and influence of UFC is unmatched by
any other sports organization, and we look forward to this partnership
spotlighting Smith+Nephew's leading-edge portfolio of Sports Medicine technology
solutions with the UFC's global audience."
Beyond the Octagon, UFC and Smith+Nephew will collaborate on original content
that will be distributed through UFC's popular digital and social channels,
which reach more than 259 million users worldwide. Smith+Nephew will also have a
branded presence throughout the UFC Performance Institutes in Las Vegas,
Shanghai and Mexico City - the world's first mixed martial arts performance
training, research, rehabilitation, and nutrition centers. The agreement also
provides for an annual Brand Ambassador fund that will bring the partnership to
life through appearances, content, and creative campaigns with UFC athletes.
- ends -
Enquiries

  Media
  David Snyder                      +1 978-749-1440
  Smith+Nephew

References
1. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus
Microfracture and Debridement for the Treatment of Knee Chondral and
Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial.

    Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252
 2. Ruiz Ibán MA, Navlet MG, Marco SM, et al.  Augmentation of a transosseous
    equivalent repair in posterosuperior non-acute rotator cuff tears with a
    bioinductive collagen implant decreases the re-tear rate at one year. A
    randomised controlled trial. Arthroscopy. Published online 12/27/2023.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair,
regeneration and replacement of soft and hard tissue. We exist to restore
people's bodies and their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this
mission every day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new technologies
across our three global business units of Orthopaedics, Sports Medicine & ENT
and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of
the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to
refer to Smith & Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com
(http://www.smith-nephew.com/)and follow us on X
(http://www.twitter.com/smithnephewplc), LinkedIn
(http://www.linkedin.com/company/smith-%26-nephew), Instagram
(https://www.instagram.com/smithnephewmeded/) or Facebook
(http://www.facebook.com/smithnephewplc).
About UFC®
UFC® is the world's premier mixed martial arts organization (MMA), with more than 700 million fans and 259 million social media followers. The organization produces more than 40 live events annually in some of the most prestigious arenas around the world while broadcasting to over 975 million TV households across more than 170 countries. UFC's athlete roster features the world's best MMA athletes representing more than 80 countries. The organization's digital offerings include UFC FIGHT PASS®, one of the world's leading streaming services
for combat sports. UFC is part of TKO Group Holdings (NYSE: TKO) and is headquartered in Las Vegas, Nevada. For more information, visit UFC.com and follow UFC at Facebook.com/UFC and @UFC on X, Snapchat, Instagram, and TikTok: @UFC.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and trading
profit margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-
placed", "believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause actual results to differ materially
from what is expressed or implied by the statements. For Smith+Nephew, these
factors include: conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and innovative
medical devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product defects or recalls
or other problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims; legal and
financial compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including acquisitions
and disposals, our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to market
developments; relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to natural disasters,
weather and climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation regulations;
effects of foreign exchange volatility; and numerous other matters that affect
us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's
most recent annual report on Form 20-F, which is available on the SEC's website
at www. sec.gov, for a discussion of certain of these factors. Any forward-
looking statement is based on information available to Smith+Nephew as of the
date of the statement. All written or oral forward-looking statements
attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does
not undertake any obligation to update or revise any forward-looking statement
to reflect any change in circumstances or in Smith+Nephew's expectations.
(? )Trademark of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office.
Â